In this article, we will list the 5 Best Penny Stocks to Buy and Hold Under $5. Please visit 10 Best Penny Stocks to Buy and Hold Under $5 if you would like to see the extended list and the methodology behind it.

5. Prime Medicine, Inc. (NASDAQ:PRME)

On April 15, 2026, Prime Medicine, Inc. (NASDAQ:PRME) announced the appointment of Svetlana Makhni as Chief Financial Officer. In this role, she will lead the company’s financial strategy and operations, including investor relations, financial planning and analysis, and corporate development.

Last month, Oppenheimer initiated coverage of Prime Medicine with an Outperform rating and an $11 price target, describing the company as a key player in the gene editing space. The firm highlighted Prime’s use of prime editing technology, which it views as a leading approach supported by early clinical data and a partnership with Bristol Myers Squibb. Oppenheimer also pointed to the company’s pipeline, including its alpha-1 antitrypsin deficiency (AATD) program, where even modest market penetration could translate into multi-billion-dollar revenue potential. The firm sees significant upside tied to upcoming catalysts over the next 10 to 15 months and noted that elevated short interest appears disconnected from fundamentals.

Earlier in March, Prime Medicine reported FY25 EPS of ($1.35) compared to ($1.65) the prior year, with revenue of $4.63M versus $2.98M. Management emphasized the company’s focus on advancing its prime editing platform to enable durable genetic corrections across a broad set of diseases, with initial efforts centered on PM359, an ex vivo autologous hematopoietic stem cell therapy for chronic granulomatous disease.

Prime Medicine, Inc. (NASDAQ:PRME) develops gene editing-based therapies targeting a range of genetic diseases.

4. SEALSQ Corp (NASDAQ:LAES)

On April 13, 2026, WISeKey (NASDAQ:WKEY) and its post-quantum subsidiary SEALSQ Corp. (NASDAQ:LAES) announced the completion of the pilot phase of their collaboration with the Swiss Armed Forces’ Space Command. The initiative, launched in 2022 and expanded in 2024, focused on assessing the technical and operational foundations for a future sovereign, quantum-resilient space communications infrastructure. The pilot included satellite missions, payload integration, and secure communications testing to evaluate architecture design, operational concepts, and potential defense applications, providing key insights for the next phase of development.

On April 7, 2026, SEALSQ reported strong momentum in Q1, with revenue of approximately $4.1M, up more than 200% from $1.3M in the same period last year. The growth was driven by increased demand across its core product lines and continued expansion of its pipeline, alongside progress in post-quantum technology development and new global partnerships.

The company reaffirmed its FY2026 guidance, expecting revenue growth of 50% to 100% year-over-year, supported by its strong start to the year and positioning in the emerging quantum-security infrastructure market.

SEALSQ Corp. (NASDAQ:LAES) develops semiconductor and cybersecurity solutions focused on post-quantum technologies across global markets.

3. Uranium Royalty Corp. (NASDAQ:UROY)

On April 20, 2026, Raymond James upgraded Uranium Royalty Corp. (NASDAQ:UROY) to Outperform from Market Perform and raised its price target to C$6.25 from C$5.75. The firm said the company provides exposure to uranium prices through a high-margin royalty model that limits operating and capital cost exposure. It also highlighted a portfolio diversified across relatively stable jurisdictions and supported by strong operators, with added upside from exploration and asset expansion alongside a solid balance sheet.

Earlier, on April 15, 2026, Uranium Royalty Corp. (NASDAQ:UROY) entered into an agreement to combine with entities holding a 92% interest in Sweetwater Royalties from funds managed by Orion Resource Partners and the Ontario Teachers’ Pension Plan. The transaction implies a 100% enterprise value of approximately $1.9B for Sweetwater and about $1.1B in attributable equity value to be acquired by URC. The combined company will operate under a newly formed U.S.-domiciled parent, “Uranium Royalty Corp.” or “New URC,” which plans to apply for a NASDAQ listing.

Under the deal, the sellers will receive approximately $330M in cash and $813M in New URC Shares at a deemed value of $3.64 per share. Orion and Ontario Teachers’ are expected to hold approximately 43% and 16% of New URC’s pro forma shares outstanding and will have board nomination rights for up to two and one directors, respectively, with total representation capped below 50%. The transaction is expected to be accretive to NAV, cash flow, and EPS, with a shareholder meeting expected on or about July and closing expected on or about Q3, subject to regulatory approvals. Following completion, Scott Melbye will remain CEO and Amir Adnani Chairman, while Sweetwater will continue under CEO Damon Barber.

Uranium Royalty Corp. (NASDAQ:UROY) operates as a pure-play uranium royalty company in Canada, the United States, Namibia, and Spain.

2. Datavault AI Inc. (NASDAQ:DVLT)

On April 15, 2026, Datavault AI Inc. (NASDAQ:DVLT) said the first sites of its quantum-ready high-performance computing GPU network are now live in New York and Philadelphia, with the full 48,000-GPU fleet expected to become commercially available beginning in Q3 2026. The company plans to deploy the fleet across 1,000 urban micro-edge neocloud sites in more than 100 U.S. cities by the end of 2026, with each site supporting up to 48 GPUs configured for low-latency AI inference and HPC workloads.

On April 13, 2026, Datavault AI Inc. (NASDAQ:DVLT) and AgSensor Solutions closed a consulting partnership agreement focused on identifying, valuing, and tokenizing high-value agricultural data assets. The partnership allows Datavault AI to use AgSensor’s expertise in agricultural technology to source and evaluate companies with data assets suited for its Information Data ExchangeB., DataScoreB., and DataValueB. blockchain tokenization platforms, targeting areas such as soil sensing, carbon and sustainability data, agricultural IoT platforms, and regenerative agriculture ESG data.

Earlier in April, the company signed $750M in aggregate tokenization contracts during Q1 2026, generating approximately $77M in associated fees tied to banking, IP licensing, minting, and related services, supporting its previously stated full-year 2026 revenue guidance of at least $200M.

Datavault AI Inc. (NASDAQ:DVLT) owns and operates data management platforms with high computing capabilities across North America, Asia Pacific, Europe, and internationally.

1. AtaiBeckley Inc. (NASDAQ:ATAI)

On April 20, 2026, Canaccord analyst Sumant Kulkarni raised the price target on Atai Beckley Inc. (NASDAQ:ATAI) to $15 from $14 and maintained a Buy rating. The firm updated its model following the company’s investor day, as BPL-003 is expected to enter Phase 3 trials this quarter, and VLS-01 Elumina Phase 2 data in treatment-resistant depression is anticipated in the second half of 2026. Canaccord’s revisions include increasing its assumed net annual price for BPL-003 to about $30,000 at launch from roughly $20,000, aligning it more closely with Spravato.

On April 16, 2026, Guggenheim raised its price target on Atai Beckley to $16 from $11 and kept a Buy rating, noting that recent discussions with management strengthened its conviction in the BPL-003 program ahead of Phase 3 initiation.

On April 7, 2026, Atai Beckley reported peer-reviewed Phase 2a results in CNS Drugs showing that a single intranasal dose of BPL-003 (mebufotenin benzoate), which has received FDA Breakthrough Therapy designation, led to rapid and sustained reductions in MADRS scores among patients with treatment-resistant depression who remained on stable SSRI therapy. The study showed a 66.7% response rate at Day 2 in both the 10 mg and 12 mg cohorts, with 83% of patients in the 10 mg group and 66.7% in the 12 mg group maintaining response at Week 12. BPL-003 was generally well tolerated, with no serious adverse events reported, and average discharge occurring about 100 minutes after dosing. Phase 3 trials are expected to begin in Q2 2026 following FDA End-of-Phase 2 alignment.

Atai Beckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders.

READ NEXT: 8 Best Beginner Stocks to Buy Right Now and 10 Fastest-Growing Financial Stocks to Invest In

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.